OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.

General. On November 23, 2016 (the
Original Issue Date) the Company entered into and closed on the
transaction set forth in the Amended and Restated Securities
Purchase Agreement (the Securities Purchase Agreement) it entered
into with three institutional investors (the Purchasers) for the
sale of the Companys convertible notes and warrants. to the terms
provided for in the Securities Purchase Agreement, the Company
issued upon closing to the Purchasers for an aggregate
subscription amount of $350,000: (i) 14.29% Original Issue
Discount 10% Senior Secured Convertible Notes (the Notes); and
(ii) warrants (the Warrants) to purchase 2,333,334 shares of the
Companys common stock, par value $0.001 per share (the Common
Stock) at an exercise price of $0.175 (subject to adjustments
under certain conditions as defined in the Warrants). The closing
under the Securities Purchase Agreement occurred on November 23,
2016.

The Notes. The aggregate principal
amount of the Notes is $350,000 and the Company will receive
$300,000 after giving effect to the original issue discount of
$50,000. The Notes bear interest at a rate equal to 10% per annum
(which interest rate is increased to 24% per annum upon the
occurrence of an Event of Default (as defined in the Notes)),
have a maturity date of July 21, 2017 and are convertible
(principal, and interest) at any time after the issuance date of
the Notes into shares of the Companys Common Stock at a
conversion price equal to $0.15 per share (subject to adjustment
as provided in the Note), provided, however, that if an event of
default has occurred, regardless of whether such Event of Default
has been cured or remains ongoing, the Note shall be convertible
at 60% of the lowest closing price during the prior twenty
trading days of the Common Stock as reported on the OTCQB or
other principal trading market (the Default Conversion Price).
The Notes provide for two amortization payments on the six-month,
seven-month and eight-month anniversary of the issue date with
each amortization payment being one third of the total
outstanding principal and interest. If the six-month amortization
payment is made in cash then the payment is an amount equal to
120% of the applicable amortization payment and if the
seven-month or the eight-month amortization payments are made in
cash then the payment is an amount equal to 125% of the
applicable amortization payment. The Notes may be prepaid at any
time until the 180th day following the Original Issue Date at an
amount equal to (i) 115% of outstanding principal balance of the
Note and accrued and unpaid interest during the period from the
Original Issue Date through the three months following the
Original Issue Date, and (ii) 120% of outstanding principal
balance of the Notes and accrued and unpaid interest during
months four through six following the Original Issue Date. In
order to prepay the Notes, the Company shall provide 20 Trading
Days prior written notice to the Holder, during which time the
Holder may convert the Notes in whole or in part at the
Conversion Price.

The Notes contain certain covenants, such as restrictions on the
incurrence of indebtedness, creation of liens, payment of
restricted payments, redemptions, payment of cash dividends and
the transfer of assets. The Notes also contains certain
adjustment provisions that apply in connection with any stock
split, stock dividend, stock combination, recapitalization or
similar transactions. The conversion price is subject to
adjustment if we issue or sell shares of our common stock for a
consideration per share less than the conversion price then in
effect, or issue options, warrants or other securities
convertible or exchange for shares of our common stock at a
conversion or exercise price less than the conversion price of
the Notes then in effect. If either of these events should occur,
the conversion price is reduced to the lowest price at which
these securities were issued or are exercisable. We granted the
Purchasers certain rights of first refusal on future offerings by
us for as long as the Purchasers hold the Notes. In addition,
subject to limited exceptions, the Purchasers will not have the
right to convert any portion of the Note if the Purchaser,
together with its affiliates, would beneficially own in excess of
4.99% of the number of shares of the Companys Common Stock
outstanding immediately after giving effect to its conversion.
The Purchaser may increase or decrease this ownership limitation
to any percentage not exceeding 9.99% upon 61 days prior written
notice to us. In addition, we granted the Purchasers certain
rights of first refusal on future offerings by us for as long as
the Purchasers hold the Notes.

The Warrants. As described above,
holders of the Notes received Warrants to purchase up to
2,333,334 shares of Common Stock. The initial exercise price for
the Warrants is $0.175 per share, subject to adjustment as
described below, and the Warrants are exercisable for five years
after the issuance date. The Warrants are exercisable for shares
of Common Stock upon the payment in cash of the exercise price
and they are also exercisable on a cashless basis at any time
there is no effective registration statement registering the
shares of Common Stock underlying the Warrants. The exercise
price of the Warrants is subject to adjustment in the event of
certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting the
Common Stock and also upon any distributions of assets, including
cash, stock or other property to the Companys stockholders. The
exercise price of the Warrants is also subject to full ratchet
price adjustment if the Company sells or grants any option to
purchase, sell or re-price any Common Stock or Common Stock
Equivalents (as defined therein) at an exercise price lower than
the then-current exercise price of the Warrant with the exception
for certain exempted issuances and subject to certain limitations
on the reduction of the exercise price as provided in the
Warrants. In the event of a fundamental transaction, as described
in the Warrants and generally including any reorganization,
recapitalization or reclassification of the Common Stock, the
sale, transfer or other disposition of all or substantially all
of the Companys properties or assets, the Companys consolidation
or merger with or into another person, the acquisition of more
than 50% of the outstanding Common Stock, or any person or group
becoming the beneficial owner of 50% of the voting power
represented by the outstanding Common Stock, the holders of the
Warrants will be entitled to receive upon exercise of the
Warrants the kind and amount of securities, cash or other
property that the holders would have received had they exercised
the Warrants immediately prior to such fundamental transaction;
provided that upon the occurrence of certain fundamental
transactions, the holder can require the Company to purchase the
Warrant for cash at a price equal to the higher of the Black
Scholes Value of the unexercised portion of the Warrant or
difference between the cash per share paid in the fundamental
transaction and the exercise price per share. The holder of
Warrants will not have the right to exercise any portion of the
Warrant if the holder (together with its affiliates) would
beneficially own in excess of 9.99% of the number of shares of
Common Stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in
accordance with the terms of the Warrants. The foregoing
description is qualified in its entirety by reference to the full
text of the form of Warrant filed as Exhibit 10.4 hereto and is
incorporated by reference into this Item 1.01.

Ancilliary Agreements. In connection
with the Companys obligations under the Notes, the Company and
its subsidiary, OncBioMune, Inc. (the Subsidiaries) entered into
a Security Agreement, Pledge Agreement and Subsidiary Guaranty
with Calvary Fund I LP, as agent, to which the Company and the
Subsidiary granted a lien on all assets of the Company and the
Subsidiary (the Collateral) excluding permitted indebtedness
which includes a first lien held by Regions Bank in connection
with the $100,000 revolving promissory note entered into with
Regions Bank in October 2014, for the benefit of the Purchasers,
to secure the Companys obligations under the Notes. Upon an Event
of Default (as defined in the Notes), the Purchasers may, among
other things, collect or take possession of the Collateral,
proceed with the foreclosure of the security interest in the
Collateral or sell, lease or dispose of the Collateral.

Additional Purchaser Rights and Company
Obligations

The Securities Purchase Agreement includes additional purchaser
rights and Company obligations including obligations on the
Company to reimburse the Purchasers $20,000 for legal fees and
expenses, satisfy the current public information requirements
under SEC Rule 144(c), obligations on the Company with respect to
the use of proceeds from the sale of securities and Purchaser
rights to participate in future Company financings. Reference
should be made to the full text of the Securities Purchase
Agreement filed as Exhibit 10.2 hereto, which is incorporated by
reference into this Item 1.01.

The foregoing description of the terms of the Securities Purchase
Agreement, the Notes, the Security Agreement, the Warrants, the
Pledge Agreement, and the Subsidiary Guaranty, do not purport to
be complete and are qualified in their entirety by reference to
the provisions of such agreements, the forms of which are filed
as exhibits 10.2, 10.3, 10.4, 10.5, 10.6 and 10.7 to this Current
Report on Form 8-K.

Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.

Information concerning the Companys issuance of the Notes and
Warrants as set forth in Item 1.01 above is incorporated herein
to this Item 2.03 by this reference.

Item 3.02 Unregistered Sales of Equity
Securities.

Information concerning the Companys issuance of the Notes and
Warrants as set forth in Item 1.01 above is incorporated herein
to this Item 3.02 by this reference.

The issuance of the Notes and the Warrants Common is exempt from
the registration requirements from the Securities Act of 1933, as
amended, to Section 4(a)(2) thereof. The Company has not engaged
in general solicitation or advertising with regard to the
issuance and sale of the Notes and the Warrants and has not
offered securities to the public in connection with such issuance
and sale.

Item 8.01 Other Events.

On November 25, 2016, the Company paid $62,000 as payment in full
for the Convertible Promissory Note in the original principal
amount of $40,000 issued to Crown Bridge Partners, LLC on May 23,
2016.

Item 9.01. Financial Statements and Exhibits.

* Filed herewith.

About OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP)

OncBioMune Pharmaceuticals, Inc., formerly Quint Media Inc., is a biotechnology company. The Company specializes in various cancer therapies. The Company focuses on developing breast and prostate cancer therapeutic vaccines, and a process for the growth of cancer cells and targeted chemotherapies. The Company’s vaccine technology is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The Company’s product portfolio consists of approximately three target therapies and a vaccine platform that allows creation of a therapeutic vaccine for various solid tumor cancer. The Company’s lead product, ProscaVax is indicated for prostate cancer. The Company focuses on planning Phase II clinical trials of ProscaVax. The Company is also focused on development of its other technologies, such as the paclitaxel-albumin conjugate. It also has a portfolio of targeted therapies, some of which are biosimilars to drugs, including paclitaxel (Abraxane).

OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Recent Trading Information

OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) closed its last trading session 00.000 at 0.140 with 24,000 shares trading hands.